CompletedNCT00563810Updated Nov 26, 2007

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

A Phase 1 interventional study of MYO-029 in Healthy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-11-26.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer · Phase 1, Interventional, and Health services research

Phase: Phase 1
Study type: Interventional
Enrollment: 72
Allocation: Randomized
Ages: 18 Years to 80 Years
Sex: All

Study summary

This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.

Conditions studied

Healthy

Keywords

Adult
Aged

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 472 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 80 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Eligibility criteria

Inclusion Criteria:

Men aged 18 to 45 years inclusive on study day 1.
Elderly men and women aged 65 to 80 years inclusive on study day 1.
Women must be postmenopausal for > or = 1 year (with estradiol \< 25 pg/mL and an FSH > 40 mIU/mL).
Healthy as determined by the investigator on the basis of medical history, physical examination, vital signs, clinical laboratory test results, and 12-leave electrocardiogram.
Elderly subjects may have stable, nonclinically significant abnormalities on physical examination, and laboratory evaluation.
Non-smoker.

Study design

Phase: Phase 1
Primary purpose: Health services research
Allocation: Randomized
Intervention model: Single group
Masking: Double
Enrollment: 72 participants

Interventions

DrugMYO-029

What researchers measure

Primary outcomes

To assess safety and tolerability.

Study locations

No study locations are listed for this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Nov 26, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00563810
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
First posted: Nov 26, 2007
Start date: Oct 2004
Completion: Apr 2006
Last update: Nov 26, 2007

Study contacts

Medical Monitor

study director · Wyeth is now a wholly owned subsidiary of Pfizer

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Start the discussion